TY - JOUR
T1 - Symptom provocation for treatment of obsessive-compulsive disorder using transcranial magnetic stimulation
T2 - A step-by-step guide for professional training
AU - Maia, Ana
AU - Almeida, Sílvia
AU - Cotovio, Gonçalo
AU - Rodrigues da Silva, Daniel
AU - Viana, Francisco Faro
AU - Grácio, Jaime
AU - Oliveira-Maia, Albino J.
N1 - Funding Information:
AM and GC were supported by doctoral fellowships from Fundação para a Ciência e Tecnologia (FCT, references SFRH/BD/144508/2019 and SFRH/BD/130210/2017, respectively). GC and AO-M were supported by grant PTDC/MED-NEU/31331/2017 from FCT and AO-M was supported by grant FCT-PTDC/MEC-PSQ/30302/2017-IC&DT-LISBOA-01-0145-FEDER, funded by national funds from FCT/Ministério da Ciência, Tecnologia e do Ensino Superior (MCTES) and cofounded by Fundo Europeu de Desenvolvimento Regional (FEDER), under the Partnership Agreement Lisboa 2020—Programa Operacional Regional de Lisboa. This work was supported by the Brain and Behavior Research Foundation (BBRF) through grant BBRF-27595-2018 NARSAD to AM and AO-M. FCT/MCTES, FEDER, and the BBRF did not have a role in the design and conduct of this work, in the preparation, review, or approval of the manuscript, nor in the decision to submit the manuscript for publication.
Funding Information:
Author AO-M was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. (2019-2020), is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. (EudraCT numbers: 2017-003288-36 and 2020-001348-25), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. (EudraCT number: 2019-002992-33). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
PY - 2022/8/3
Y1 - 2022/8/3
N2 - Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique that was cleared by the Food and Drug Administration (FDA) for the treatment of Obsessive-Compulsive Disorder (OCD) in 2018. The approved protocol includes individualized symptom provocation before each stimulation session, to elicit a moderate level of obsessional distress. Although symptom provocation can be a delicate, demanding, and uncomfortable procedure, structured training methods for those who are going to apply it are not available. Here, we describe a model for training in symptom provocation for TMS technicians, developed at the Champalimaud Clinical Centre in Lisbon, Portugal. Our programme includes two-sessions dedicated to clinical communication and symptom provocation techniques from a theoretical and practical perspective. Additionally, supervision meetings are conducted during treatment of patients, allowing regular case discussion and redefinition of symptom provocation hierarchy, as needed. In addition to having a strong practical component, our training program is short and pragmatic, allowing for easy implementation and fluid transition to clinical practice. By sharing our experience, we hope to contribute to systematize training procedures required for symptom provocation in the context of TMS, and to qualitatively describe a methodology that can be used for implementation of TMS programmes for the treatment of OCD.
AB - Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique that was cleared by the Food and Drug Administration (FDA) for the treatment of Obsessive-Compulsive Disorder (OCD) in 2018. The approved protocol includes individualized symptom provocation before each stimulation session, to elicit a moderate level of obsessional distress. Although symptom provocation can be a delicate, demanding, and uncomfortable procedure, structured training methods for those who are going to apply it are not available. Here, we describe a model for training in symptom provocation for TMS technicians, developed at the Champalimaud Clinical Centre in Lisbon, Portugal. Our programme includes two-sessions dedicated to clinical communication and symptom provocation techniques from a theoretical and practical perspective. Additionally, supervision meetings are conducted during treatment of patients, allowing regular case discussion and redefinition of symptom provocation hierarchy, as needed. In addition to having a strong practical component, our training program is short and pragmatic, allowing for easy implementation and fluid transition to clinical practice. By sharing our experience, we hope to contribute to systematize training procedures required for symptom provocation in the context of TMS, and to qualitatively describe a methodology that can be used for implementation of TMS programmes for the treatment of OCD.
KW - guide
KW - obsessive-compulsive disorder
KW - structured training
KW - symptom provocation
KW - transcranial magnetic stimulation
UR - http://www.scopus.com/inward/record.url?scp=85136207203&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2022.924370
DO - 10.3389/fpsyt.2022.924370
M3 - Article
C2 - 35990054
AN - SCOPUS:85136207203
SN - 1664-0640
VL - 13
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 924370
ER -